2022-2023 Flu Season Changes and Survey
Flu Season Planning Survey
Please complete our 2022-23 Flu Season Planning Survey by Friday, 1/21. Your responses are key in our planning for the next flu season.
Changes for the 2022-2023 Flu Season
The FDA recently approved the expansion of the age range for a cell based manufactured vaccine, Flucelvax. Under this expansion Flucelvax can be administered to individuals 6 months of age and older.
The flu viruses used in the cell-based vaccines are grown in cultured cells of mammalian origin instead of in hens’ eggs. Most inactivated flu vaccines are produced by growing flu viruses in eggs.
Cell-based flu vaccine production does not use flu viruses grown in eggs and, therefore, is not dependent on the supply of eggs. In addition, cell-based flu vaccines have the potential to offer better protection than traditional, egg-based flu vaccines.
The viruses used to make cell-based vaccines may be more similar to circulating “wild” flu viruses than the viruses used to make egg-based vaccines. Growing flu viruses in eggs can introduce changes (called egg-adapted changes) that can cause differences between the viruses in the vaccine and the ones that are circulating. These changes may have important implications for the body’s immune response to vaccination. For example, egg-adapted changes could cause the body’s immune system to produce antibodies that are less effective at preventing disease caused by the specific flu viruses in circulation.
You can find more information about the types of flu vaccines approved for use in the US on the CDC website here:
Flu Vaccines: https://www.cdc.gov/flu/prevent/different-flu-vaccines.htm
Recombinant Flu Vaccines: https://www.cdc.gov/flu/prevent/qa_flublok-vaccine.htm
Cell-Based Vaccines: https://www.cdc.gov/flu/prevent/cell-based.htm
Flucelax Package Insert: https://www.fda.gov/media/115862/download